Neutralizing antibody response to SARS-CoV-2 variants, as determined by the MSD multiplex assay, following COVID-19 vaccination in cancer patients
{{output}}
Background: Immunocompromised populations, especially cancer patients, rely on the effectiveness of the COVID-19 vaccines to protect against severe infection or death, both against the original wild-type (WT) SARS CoV-2 virus and... ...
